103 results about "Disaccharidase" patented technology

Qualitative and quantitative methods of testing an agent for its potential at inhibiting glycosidase catalytic activity, the methods including the steps of interacting a glycosidase enzyme with a glycosidase substrate in a presence of the agent and qualitatively or quantitatively evaluating an effect of the agent on the catalytic activity of the glycosidase enzyme toward the glycosidase substrate. Preferably the glycosidase enzyme is a heparanase enzyme and the glycosidase substrate is, respectively, a heparanase substrate.

The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft for implantation into humans. The invention further provides a method for preparing a bone xenograft by removing at least a portion of a bone from a non-human animal to provide a xenograft (X); washing the xenograft in saline and alcohol; subjecting the xenograft to a cellular disruption treatment; and treating the xenograft with a glycosidase to remove surface carbohydrate moieties. The invention also provides an article of manufacture produced by the above identified method of invention. The invention further provides a bone xenograft for implantation into a human including a portion (10) of a bone from a nonhuman animal, wherein the portion has substantially no surface carbohydrate moieties which are susceptible to glycosidase digestion. Each xenograft of the invention has substantially the same mechanical properties as a corresponding native bone.

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac.

The present invention discloses an alginic acid and/or its salts with low molecular weight, wherein the weight average molecular weight of the alginic acid is from about 700 to about 4500 Daltons, and the molar ratio of guluronic acid to mannuronic acid in the alginic acid is from about 0.6 to about 19. The present invention also discloses the preparative method of making the alginic acid and/or its salts thereof, and the use of them for treating hypertension, chronic renal failure and postprandial hyperglycemia induced by glycosidase. The present invention further discloses pharmaceutical compositions and foods containing the alginic acid with low molecular weight and/or salts thereof as active component.

The invention discloses a separation and purification method of main catechin components in tea polyphenol and glycosidase activity thereof. In the separation and purification method, tea polyphenol extracts are absorbed by macroporous adsorption resin of nonpolar or weak polar polystyrene; water and ethanol are used for the elution; alcohol eluates, through polyamide columns for the chromatography and are eluted respectively by water and ethanol. The water recrystallization is carried out on the alcohol eluates of the polyamide columns to obtain EGCG pure products with the purity larger than 95 percent and the yield larger than 50 percent; reversed-phase C18 filled columns are used for the chromatography of water eluates of the polyamide columns to obtain EC and EGC; the ethanol of 50-80 percent is used for the recrystallization to obtain pure products of the EC and EGC with the purity all larger than 96 percent. Tests in vitro show that EGCG, EGC and EC all have inhibitory activity on alpha-glucosidase and alpha-amylase and can be used for preparing weight reduction products reducing the absorption of carbohydrates or drugs or health products lowering the postprandial blood glucose.

The invention provides a beta-glucosidase, a preparation method and application of beta-glucosidase, belonging to the field of genetic engineering technology and biological medicine. The beta-glucosidase is selected from the protein shown as (1) or (2) as follows: (1) the protein with amino acid sequence shown as SEQ ID NO.1 and (2) the protein with glycosidase activity and with one/more amino acid residue substituted and/or deleted and/or added in the amino acid residue sequence. The beta-glucosidase provided by the invention has high heat stability and wide pH enzymolysis scope, can be used for producing rare ginsenoside and mixture thereof, has relatively high hydrolysis capacity, is capable of converting the ginsenoside into the rare ginsenoside which has relatively high biological activity, is capable of being easily efficiently absorbed by a human body and has trace volume in the plants such as ginseng, and can be applied to various fields of food, medicine health, and the like.

The invention relates to a pharmaceutical composition having alpha-glucosidase inhibition activity, wherein the pharmaceutical composition comprises a flavone compound and an alpha-glucosidase inhibitor, the flavone compound is at least one selected from a monomer such as baicalein, quercetin, luteolin, baicalein-7-O-glucoside and catechin, an organic salt of the monomer, and an inorganic salt of the monomer, and the alpha-glucosidase inhibitor is at least one selected from a monomer such as acarbose, voglibose and miglitol, an organic salt of the monomer, and an inorganic salt of the monomer. According to the present invention, the pharmaceutical composition can effectively reduce postprandial blood glucose, can inhibit the activity of alpha-glucosidase adopting starch, maltose and sucrose as substrates, and less uses the alpha-glucosidase inhibitor, such that the efficacy can be improved, the side effect of the alpha-glucosidase inhibitor can be effectively reduced, and hypoglycemia and other problems easily caused by drug combination are effectively solved.

The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.

The invention relates to an extraction method of natural anthocyanidin active aglycone, which belongs to the technical field of bioengineering. The method comprises the following steps: performing classification, crushing, water absorption, freezing, heating for unfreezing, and filtering for juice preparation of anthocyanidin-containing plants, performing biodegradation of anthocyanin by glycosidase for decomposing anthocyanin glucosidic bonds, performing combination reaction precipitation/suspension by an anionic surfactant, degrading the precipitates/suspensions by bacterial microbe, and performing sterilization, enzyme and bacterium filtration, and freeze drying of the anthocyanidin aqueous solution. The method of the invention can obtain cationic anthocyanidin, instead of anthocyanin, with a real content of more than 95%. The cationic anthocyanidin prepared by the method of the invention needs no degradation by microbe in human body intestinal tracts, can be absorbed and used directly by human body, or can directly enter human body blood, and is applicable to medicine and health care.

The invention provides an article of manufacture comprising a substantially non-immunogenic xenograft for implantation into humans. The invention also provides methods for preparing a xenograft by removing at least a portion of a soft tissue from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to cellular disruption treatment; treating the xenograft with crosslinking agents, and digesting the xenograft with a proteoglycan-depleting factor and/or glycosidase. The invention further provides a method for sterilizing xenograft material, having the steps of obtaining substantially non-immunogenic xenograft material; treating the xenograft material with at least one crosslinking agent; and subjecting the crosslinked xenograft material to radiation treatment.

Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of: reacting aminoacetophenone with sulfonylchloride under the presence of an appropriate salt; and reacting the compound prepared in the above step with hydroxybenzaldehide under the presence of an appropriate catalyst. The chalcone derivative of formula 1 in accordance with the present invention having strong enzyme inhibitory activities for glycosidase can be effectively used in preventing and treating various diseases induced by glycosidase, and the chalcone derivative of the invention having tyrosinase and melanin synthesis inhibitory activities can be effectively used as a skin-whitening compound.

Synthesis of an amino-disaccharide, amino-oligosaccharide or a derivative thereof, characterized in that a monosaccharide, a disaccharide, an oligosaccharide, a glycoside or a derivative thereof, in the presence of a glycosidase as catalyst, is reacted with an amino-deoxy-saccharide or a glycoside or derivative thereof, and that the amino-saccharide is optionally isolated from the product mixture directly or after chemical/enzymatic modification.

The invention provides applications of four kaurane diterpene compounds in preparation of glycosidase inhibitor medicines. The four compounds capable of highly inhibiting alpha-glycosidase activity are natural compounds which are high in safety and capable of rapid natural degradation without residue in the environment. The four compounds are obtained by separation from wedelia trilobata, and other plant materials. The plant materials are rich in source. A preparation process is easy in operation. Monomers of the four compounds are stable and liable to store. The alpha-glucosidase inhibition activity of the four compounds is obviously higher than or equivalent to that of acarbose that is a clinic medicine. The four compounds are extremely likely developed into effective and safe alpha-glucosidase inhibitor medicines used for preventing and treating type II diabetes, and have good prospects.

The invention provides a preparation method of spermacoce latifolia triterpenoids and an application of the spermacoce latifolia triterpenoids in preparation of a glycosidase inhibitor medicine. Six compounds for intensively inhibiting the activity of alpha-glycosidase provided by the invention are natural compounds which are high in safety, and can be naturally degraded rapidly without a residue in the environment. The compounds can be separated from plant materials such as spermacoce latifolia; the plant materials are abundant in source; and the preparation process is easy to operate. Monomers of the six compounds are relatively stable and easy to store; the alpha-glycosidase inhibiting activity is obviously higher than that of clinical medicine acarbose; and the compounds are extremely likely to be further developed into the effective and safe alpha-glycosidase inhibitor medicines for preventing and treating type 2 diabetes mellitus, and have relatively good prospects.

The invention provides an icaritin preparation method which comprises the following steps: a, performing the enzymatic hydrolysis reaction of an epimedium extract under the action of Beta-glycosidase; b, filtering an enzymatic hydrolysis reaction product obtained in step a; c, dissolving filter cake obtained after filtration into acetone; and d, adding water to an acetone solution, performing reflux dissolution, keeping the solution standing, performing filtration, and collecting a crystal substance to obtain icaritin. According to the icaritin preparation method, the yield of icaritin is up to 20% relative to the epimedium extract, and the purity of icaritin is up to 99.8%.

The invention provides a preparation method of glycosylated hesperetin. The preparation method comprises the specific steps that raw materials and a glycosyl donor are put into a reaction buffer solution; after the materials and the solution are mixed evenly, glycosidase and glycosyl transferase are added in a reaction system, wherein the raw materials are hesperidin, hesperetin, an extract or a conversion product of neohesperidin and a derivative thereof. According to the prepared glycosylated hesperetin, 1-9 glycosyl groups are added on a flavonoid parent, so that the solubility of the hesperetin is greatly improved, the problem of poor solubility of the hesperetin is solved, the problems about decomposition and absorption of the hesperetin in the human body are also solved, and the bioavailability of the hesperetin in citrus is greatly improved.

The invention provides a glycosidase producing strain, that is, Aspergillus niger JH-2 and an application of the Aspergillus niger JH-2 to biotransformation and increasing of the content of asiatic acid in centella asiatica. The Aspergillus niger is a common strain in the fermentation industry and is non-toxic, harmless and safe to use, the converting culture medium is simple in component, only five salt components are needed, and the production cost is low; the Aspergillus niger JH-2 grows fast and is high in infectious microbe resistance, easy to culture and stable in batch. Dry centella asiatica powder is taken as a raw material and fed into the culture medium for conversion, asiaticoside separation and extraction operations are omitted, separation and purification steps of enzyme are also omitted, the process is simple, and industrial application is facilitated; the content of the asiatic acid can be increased by 3 times at most after the centella asiatica powder is subjected to biotransformation treatment.

The invention relates to a method for producing methane by utilizing enzyme to process organisms. The method includes the steps that pig manure is weighted and fermentation liquid is prepared according to the concentration of the total content of solids (TS) of the pig manure; Alpha-amylase or Gamma-amylase is added to the prepared fermentation liquid for processing the liquid; the processed fermentation liquid is mixed with inoculum for the fermentation of the methane. The method adopts amylase for the pre-processing of the fermentation of the pig manure and the result shows that the degradation rate of the TS and the VS of the pig manure, the methane yield factor in the maximum volume, the accumulated methane yield and the potential of the raw materials for methane yield have remarkable growth compared with a comparison group, wherein, the processing effect of disaccharidase is better than that of the Alpha-amylase while the processing effect of the Alpha-amylase is better than that of the Gamma-amylase.

The invention provides deglycosylated holothurian secondary saponin and a preparation method of the deglycosylated holothurian secondary saponin. For the deglycosylated holothurian secondary saponin, two rear glycosyl radicals on carbohydrate chains of holothurian A (HA) and Echinoside A (EA) are removed through the enzymolysis of glycosidase, and thus the secondary saponin is obtained. The preparation method of the secondary saponin comprises the following steps: alcohol digestion, crude extraction adopting macroporous resin, and purification adopting a silicagel column, thus HA and EA are obtained, finally, enzymolysis is carried out by adopting glycosidase, and thus deglycosylated HA secondary saponin and EA secondary saponin are obtained respectively. According to the deglycosylated holothurian secondary saponin and the preparation method of the deglycosylated holothurian secondary saponin, through the used glycosidase, holothurian saponin forms secondary saponin through enzymolysis under the mild condition, so that the toxicity of holothurian saponin is reduced, and the biological activity of holothurian saponin is improved; meanwhile, glycosidase is adopted for enzymolysis of holothurian saponin, so that the side reaction and by-products brought by micro-biological degradation or degradation adopting crude enzyme extracted from microbes are avoided, the purity and yield of the enzymolysis products are improved, the single product can be obtained, and the purity can achieve 100%.

The invention relates to a blood glucose adjusting health food taking mulberry seed powder as an effective component, which comprises the following components in parts by weight: 4-99.9 parts of mulberry seed powder, 0-10 parts of flavor agent and 0.1-96 parts of accessory substance. The mulberry seed contains 1-deoxynojirimycin (DNJ) with high concentration, can inhibit the activity of small intestine alpha-glycosidase and can adjust blood glucose, thereby having obvious effect on treating human diabetes and obesity. In the invention, the mulberry seed powder is combined with the flavor agent, the accessory substance and natural products are processed into different types of health foods with the function of adjusting human blood glucose without any toxic or side effect, the safety is high, the taste flavor is good, the edibility is strong so as to control the blood glucose of a diabetic patient in the normal diet process, and simultaneously, natural resources are developed.